Symptom improvement at 3 months with ELMIRON®

Symptom improvement at 3 months

  • The Physician's Usage Study was a prospectively designed, open-label, retrospective analysis of 2499 patients who received ELMIRON® (pentosan polysulfate sodium) 300 mg/day
  • Patients' pain/discomfort scores were evaluated every 3 months
  • The end points of the study were the patient rating of overall change in pain from baseline and the change in pain/discomfort score from baseline

Results

  • 29% of all patients (722 of 2499) enrolled reported symptom improvement at 3 months*‡
  • 61% of patients (722 of 1192) who continued treatment for 3 months experienced improvement in symptoms†‡

In a separate, double-blind, randomized, placebo-controlled study, 38% of patients taking ELMIRON® 300 mg/day reported at 3 months a greater than 50% improvement in bladder pain compared with 18% of patients taking placebo (N=151).§

Symptom improvement may be gradual

  • Clinical response may require 3 to 6 months of continuous therapy

*2499 patients received at least 1 dose of ELMIRON®.
†1192 of 2499 patients received ELMIRON® treatment for 3 months.
‡Pain scores that improved by 1 or 2 categories.
§N=128 patients in 300-mg/day group. Patient's Overall Rating of Improvement of Symptoms (PORIS) response is based on all patients, not completers.